General Information of Drug (ID: DMQ4X7Y)

Drug Name
443C81
Synonyms BW 443C; BW-443C81
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Terminated [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 682.7
Logarithm of the Partition Coefficient (xlogp) -1
Rotatable Bond Count (rotbonds) 16
Hydrogen Bond Donor Count (hbonddonor) 8
Hydrogen Bond Acceptor Count (hbondacc) 10
Chemical Identifiers
Formula
C31H42N10O8
IUPAC Name
[N'-[(4S)-4-[[(2R)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]-5-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(4-nitrophenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentyl]carbamimidoyl]azanide
Canonical SMILES
C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CNC(=O)[C@H](CCCN=C(N)[NH-])NC(=O)[C@@H](CC3=CC=C(C=C3)O)[NH3+])C(=O)N
InChI
InChI=1S/C31H42N10O8/c32-22(15-18-7-11-21(42)12-8-18)28(45)39-23(3-1-13-36-31(34)35)29(46)37-17-26(43)38-24(16-19-5-9-20(10-6-19)41(48)49)30(47)40-14-2-4-25(40)27(33)44/h5-12,22-25H,1-4,13-17,32H2,(H10,33,34,35,36,37,38,39,42,43,44,45,46)/t22-,23+,24+,25+/m1/s1
InChIKey
CQEKFKUITZRTPQ-ROHNOIKCSA-N
Cross-matching ID
PubChem CID
101630908
TTD ID
D0E8SE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Asthma
ICD Disease Classification CA23
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000227)
2 Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985). 1992 Mar;72(3):1096-100.